Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
Completed
Children's Hospital of Philadelphia
N/A
1998-05-01
OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor
I (IGF-I) on insulin secretion in children with hyperinsulinism.
II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this
patient population.
III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other
insulin dependent parameters, in this patient population.
Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
Completed
FDA Office of Orphan Products Development
N/A
1998-05-01
OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor
I (IGF-I) on insulin secretion in children with hyperinsulinism.
II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this
patient population.
III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other
insulin dependent parameters, in this patient population.
Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men
Completed
Rijnstate Hospital
Phase 2
2004-11-01
The purpose of this study is to explore diazoxide efficacy in treatment of obese men and
assessment of maximal insulin suppression in obese men without hyperglycaemia.
Obesity is associated with markedly elevated plasma insulin levels throughout the day. The
concept is that obese subjects predominantly develop lean tissue resistance against the
glucoregulatory actions of insulin, but remain relatively sensitive to the lipogenic and
antilipolytic effects of insulin in adipose tissue. According to this theory, suppression of
hyperinsulinism by diazoxide, a well known inhibitor of glucose stimulated insulin secretion,
might be useful to treat obesity because it will help to reverse the process of lipid
storage.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
